Ignite Creation Date:
2025-12-25 @ 1:14 AM
Ignite Modification Date:
2025-12-27 @ 3:26 AM
Study NCT ID:
NCT01407393
Status:
COMPLETED
Last Update Posted:
2013-10-08
First Post:
2011-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D009765', 'term': 'Obesity'}, {'id': 'D015431', 'term': 'Weight Loss'}], 'ancestors': [{'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D001836', 'term': 'Body Weight Changes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 124}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-10', 'completionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-10-07', 'studyFirstSubmitDate': '2011-06-30', 'studyFirstSubmitQcDate': '2011-08-01', 'lastUpdatePostDateStruct': {'date': '2013-10-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-08-02', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'weight loss', 'timeFrame': '12 weeks', 'description': 'The primary endpoint of this randomized, double-blind, placebo-controlled bicen-tric study is to assess the weight loss effect of Glucosanol™ (kg), in combination with a weight loss program in overweight and obese subjects.'}], 'secondaryOutcomes': [{'measure': 'Proportion body weight', 'timeFrame': '12 weeks', 'description': 'To assess the efficacy of Glucosanol™ to increase the proportions of subjects who lose at least 3% and 5% of baseline body weight'}, {'measure': 'waist circumference', 'timeFrame': '12 weeks', 'description': 'Changes in waist circumference'}, {'measure': 'hip circumference', 'timeFrame': '12 weeks', 'description': 'Changes in hip circumference'}, {'measure': 'waist-hip-ratio', 'timeFrame': '12 weeks', 'description': 'Changes in waist-hip-ratio'}, {'measure': 'BMI', 'timeFrame': '12 weeks', 'description': 'Changes in BMI'}, {'measure': 'body fat', 'timeFrame': '12 weeks', 'description': 'Changes in body fat (% and kg) and fat free mass (kg)'}, {'measure': 'hunger', 'timeFrame': '12 weeks', 'description': 'Changes in hunger, eating, and food craving-related items from a Control of Eating Questionnaire'}, {'measure': 'Global evaluation of feeling of satiety', 'timeFrame': '12 weeks', 'description': 'This parameter will be assessed by a 4 points categorical scale'}, {'measure': 'Global evaluation of the efficacy', 'timeFrame': '12 weeks', 'description': 'This parameter will be assessed by a 4 points categorical scale'}, {'measure': 'Global evaluation of safety', 'timeFrame': '12 weeks', 'description': 'This will be assessed by both investigators and subjects by a 4 points categorical scale.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['overweight', 'obesity', 'weight loss', 'body fat', 'waste cirumference', 'satiety', 'appetite'], 'conditions': ['Overweight and Obesity']}, 'descriptionModule': {'briefSummary': 'Glucosanol™, the medical device to be investigated contains a proprietary plant extract that is a natural inhibitor of alpha-amylase and can reduce starch digestion.\n\nThe rationale for this study is to confirm that Glucosanol™ ingestion will reduce body weight. A double-blind, randomized, placebo-controlled design has been chosen to assess the efficacy and safety of Glucosanol™ in subjects who are overweight and mildly obese.', 'detailedDescription': 'Preparations that reduce absorption of calories from dietary carbohydrates could be decisively meaningful for the regulation of bodyweight or obesity. Hence, Glucosanol™ may be used as a tool for the treatment of obesity and weight management through reduced carbohydrate absorption.\n\nThe rationale for this study is to confirm that Glucosanol™ ingestion will reduce body weight. A double-blind, randomized, placebo-controlled design has been chosen to assess the efficacy and safety of Glucosanol™ in subjects who are overweight and mildly obese.\n\nThe specific hypotheses to be accepted or rejected by statistical data from the clinical investigation are beneficial effects of the device on weight loss (kg) and body fat content.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age 18 to 60 years\n* BMI between 25 and 35\n* Expressed desire for weight loss\n* Accustomed to 3 main meals/day\n* Consistent and stable body weight 3 months prior to study enrolment\n* Commitment to avoid the use of other weight loss products during study\n* Commitment to adhere to diet recommendation\n* Females' agreement to use appropriate birth control methods during the active study period\n* Subject declares in writing his/her consent to participate, understands requirements of the study and is willing to comply\n\nExclusion Criteria:\n\n* Known sensitivity to the ingredients of the device\n* History of Diabetes mellitus\n* Fasting blood glucose \\>7 mmol/L\n* History or clinical signs of endocrine disorders which may influence body weight (e.g., Cushing's disease, thyroid gland disorders)\n* Clinically relevant excursions of safety parameter\n* Current use of anti-depressants\n* Presence of acute or chronic gastrointestinal disease (e.g., IBD, coeliac disease. pancreatitis)\n* Uncontrolled hypertension (\\>160/110 mm Hg)\n* Stenosis in the GI tract\n* Bariatric surgery\n* Abdominal surgery within the last 6 months prior to enrollment\n* History of eating disorders such as bulimia, anorexia nervosa within the past 12 months\n* Other serious organ or systemic diseases such as cancer\n* Any medication that could influence GI functions such as antibiotics, laxatives, opioids, glucocorticoids, anticholinergics, or antidiarrheals (e.g., loperamide; must have stopped 1 months before study start)\n* Pregnancy or nursing\n* Any medication or use of products for the treatment of obesity\n* More than 3 hours strenuous sport activity per week\n* History of abuse of drugs, alcohol or medication\n* Smoking cessation within 6 months prior to enrolment\n* Inability to comply due to language difficulties\n* Participation in similar studies or weight loss programs within 3 months prior to enrolment\n* Participation in other studies within 4 weeks prior to enrollment"}, 'identificationModule': {'nctId': 'NCT01407393', 'briefTitle': 'Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects', 'organization': {'class': 'INDUSTRY', 'fullName': 'InQpharm Group'}, 'officialTitle': 'Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects', 'orgStudyIdInfo': {'id': 'INQ/K/003411'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Glucosanol', 'description': 'Glucosanol', 'interventionNames': ['Device: Glucosanol']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo', 'interventionNames': ['Device: Placebo']}], 'interventions': [{'name': 'Glucosanol', 'type': 'DEVICE', 'description': '2 tablets 3x daily for 12 weeks', 'armGroupLabels': ['Glucosanol']}, {'name': 'Placebo', 'type': 'DEVICE', 'description': '2 tablets 3x daily for 12 weeks', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '10709', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Barbara Grube', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}], 'overallOfficials': [{'name': 'Barbara Grube, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'InQpharm Group', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}